KFSHRC Celebrates Landmark Contributions at 2024 NYC C3 Summit Davos of Healthcare
September 18, 2024 06:00 ET
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Celebrates Landmark Contributions at 2024 NYC C3 Summit Davos of Healthcare
KFSHRC at the forefront of precision medicine and genomic therapies in Saudi Arabia and the region
September 17, 2024 08:48 ET
|
King Faisal Specialist Hospital & Research Centre
KFSHRC at the forefront of precision medicine and genomic therapies in Saudi Arabia and the region
KFSHRC Drives Saudi Arabia’s Rise as Global Biotech Powerhouse
September 17, 2024 04:29 ET
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Drives Saudi Arabia’s Rise as Global Biotech Powerhouse
KFSHRC Deputy CEO Receives Global Innovative Healthcare & Impact Transformation Award at New York Summit
September 16, 2024 14:06 ET
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Deputy CEO Receives Global Innovative Healthcare & Impact Transformation Award at New York Summit
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
September 15, 2024 03:00 ET
|
23andMe, Inc.
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and...
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
September 15, 2024 03:00 ET
|
23andMe, Inc.
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human...
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
September 12, 2024 16:05 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, in collaboration with lead researchers at...
Noom Introduces Industry-First $149 Compounded GLP-1 with a Taper-Off Guarantee, Offering a Sustainable Approach to Long-Term Weight Loss
September 12, 2024 08:03 ET
|
Noom Inc
Noom will offer compounded GLP-1 injections paired with Noom’s powerful GLP-1 companion program, providing a sustainable pathway off the medications.
KFSHRC Leads in Infectious Disease Diagnostics with Advanced Genomic Technologies
September 12, 2024 04:21 ET
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Leads in Infectious Disease Diagnostics with Advanced Genomic Technologies
Le PIONeeR Project présentera pour la première fois les résultats de son étude clinique de phase Ib/IIa lors de l’ESMO 2024
September 12, 2024 04:21 ET
|
The PIONeeR Project
Le PIONeeR Project présentera pour la première fois les résultats de son étude clinique de phase Ib/IIa lors de l’ESMO 2024 Le symposium présidentiel "Eyes to the future" sera l'occasion de présenter...